MARI — Marinomed Biotech AG Income Statement
0.000.00%
Last trade - 00:00- €22.05m
- €50.23m
- €9.18m
Annual income statement for Marinomed Biotech AG, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 6.14 | 8.12 | 11.6 | 11.3 | 9.18 |
| Cost of Revenue | |||||
| Gross Profit | -0.512 | -0.642 | 1.42 | 2.14 | 1.14 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 12.4 | 13.9 | 15.8 | 16.2 | 14.3 |
| Operating Profit | -6.21 | -5.82 | -4.14 | -4.91 | -5.13 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -7.21 | -6.01 | -5.69 | -6.39 | -6.79 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -7.22 | -6.01 | -5.89 | -6.4 | -6.79 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -7.22 | -6.01 | -5.89 | -6.4 | -6.79 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -7.22 | -6.01 | -5.89 | -6.4 | -6.79 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -5.2 | -4.08 | -3.99 | -4.27 | -4.48 |
| Dividends per Share |